1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

CHI's Oncology Clinical Trials Offers Five Presentations on Biomarker Driven Cancer Clinical Trials

CHI’s Oncology Clinical Trials: Bringing Effective and Safe Cancer Therapy to Patient takes place Feb. 13-15, 2013 at the Moscone in San Francisco, CA. This conference is part of the many program options available at the Molecular Med TRI-CON 2013.

 
PRLog - Jan. 10, 2013 - NEEDHAM, Mass. -- Needham Ma -  Oncology Clinical Trials conference takes place February 13-15, 2013 in San Francisco, California as part of the 20th Anniversary Molecular Med Tri-Con (TriConference.com). Don't miss these five featured presentations on Cancer Clinical Trials is the Era of Personalized Medicine PLUS a Panel Discussion on Bringing Targeted and Tailored Therapies to Patient.

Case Study of I-SPY2 Trial
Laura Jean Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology, University of California San Francisco
Screening phase II agents for neoadjuvant breast cancer, matching drugs with patients depending on biomarker subsets, including modeling longitudinal information about individual patients and using adaptive randomization.

Personalizing NSCLC Therapy: The BATTLE-2 Program
Vassiliki Papadimitrakopoulou, M.D., Professor, Department of Thoracic/Head and Neck Medical Oncology, Medical Oncology, The University of Texas MD Anderson Cancer Center
Comparing the efficacy of experimental therapies within biomarker subsets of non-small-cell lung cancer using adaptive randomization with primary endpoint 8-week disease control.

Beyond I-SPY 2 and BATTLE
Donald Berry, Ph.D., Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Extending the I-SPY 2 and BATTLE trial designs beyond breast and non-small-cell cancer, incorporating combinations of experimental agents and adapting therapies within as well as across patients.

BATTLE-2 and I-SPY 2: The Industry Perspective
Emmett V. Schmidt, M.D., Ph.D., Senior Principal Scientist, Clinical Research, Merck Research Laboratories - Oncology

KEYNOTE PRESENTATION: Novel Strategies for Biomarker - Driven Clinical Trials  
Sandra J. Horning, M.D., Senior Vice President, Global Head, Clinical Development Hematology/Oncology, Genentech  

Featured Panel

Bringing Targeted and Tailored Therapies to Patient
Moderator:
- Donald Berry, Ph.D., Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center

Panelists:
- Laura Jean Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology,  University of California San Francisco
- Vassiliki Papadimitrakopoulou, M.D., Professor, Department of Thoracic/Head and Neck Medical Oncology, Medical Oncology, The University of Texas MD Anderson Cancer Center
- Emmett V. Schmidt, M.D., Ph.D., Senior Principal Scientist, Clinical Research, Merck Research Laboratories - Oncology
- Sandra J. Horning, M.D., Senior Vice President, Global Head, Clinical Development Hematology/Oncology, Genentech

As part of the Molecular Med TRI-CON 2013, attendees have access to a partnering forum, 5 symposia, 18 short courses, and 12 core programs. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.

Registration discounts are available until January 11, 2013.  For complete event details visit: http://www.triconference.com/cct

To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at lscimemi@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

--- End ---

Click to Share

Contact Email:
***@healthtech.com Email Verified
Source:Cambridge Healthtech Institute
Phone:781.972.5400
Zip:02494
Location:Needham - Massachusetts - United States
Industry:Biotech, Medical
Tags:cancer clinical trials, oncology clinical trials, chi, san francisco, triconference
Shortcut:prlog.org/12057046
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share